Showing results (11-20 of 47) with videos related to
Sort By:
Pageof 5
European Journal of Neurology|January 15, 2021
Is the Symbol Digit Modalities Test a useful outcome in secondary progressive multiple sclerosis?Marcus W Koch, Jop Mostert, Pavle Repovic, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|July 26, 2021
MRI brain volume loss, lesion burden, and clinical outcome in secondary progressive multiple sclerosisMarcus W Koch, Jop Mostert, Pavle Repovic, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|December 30, 2021
Impact of clinical outcomes and imaging measures on health-related quality of life in secondary progressive MSMarcus W Koch, Jop Mostert, Pavle Repovic, et al.Journal of Neurology|August 15, 2021
Smoking, obesity, and disability worsening in PPMS: an analysis of the INFORMS original trial datasetMarcus W Koch, Jop Mostert, Pavle Repovic, et al.Journal of Neurology|May 15, 2022
The timed 25-foot walk is a more sensitive outcome measure than the EDSS for PPMS trials: an analysis of the PROMISE clinical trial datasetMarcus W Koch, Jop Mostert, Pavle Repovic, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|July 25, 2022
The MSIS-29 and SF-36 as outcomes in secondary progressive MS trialsEva Mm Strijbis, Pavle Repovic, Jop Mostert, et al.European Journal of Neurology|June 12, 2023
Threshold definitions for significant change on the timed 25-foot walk and nine-hole peg test in primary progressive multiple sclerosisMarcus W Koch, Pavle Repovic, Jop Mostert, et al.Multiple Sclerosis and Related Disorders|December 3, 2022
The nine hole peg test as an outcome measure in progressive MS trialsMarcus W Koch, Pavle Repovic, Jop Mostert, et al.Neurology and Therapy|November 23, 2020
Effectiveness of Dimethyl Fumarate in Patients With Relapsing Multiple Sclerosis Switching After Suboptimal Response to Glatiramer Acetate, Including Patients With Early Multiple Sclerosis: Subgroup Analysis of RESPONDPavle Repovic, Derrick Robertson, Kiren Kresa-Reahl, et al.European Journal of Neurology|December 20, 2021
Early first-line treatment response and subsequent disability worsening in relapsing-remitting multiple sclerosisMarcus W Koch, Jop Mostert, Pavle Repovic, et al.Pageof 5